Hunter Syndrome Market Size, Share, Epidemiology, Competitive Analysis Report 2030

1. Hunter syndrome is also known as Mucopolysaccharidosis type II (MPS II). It is a condition that affects many different parts of the body and mainly affects males. It is a progressive disorder, but the rate of progression varies among affected individuals. It is a rare, X-linked disorder caused due to a deficiency of the lysosomal enzyme iduronate-2- sulfatase, which plays a major role in the catabolism of glycosaminoglycans (GAG). DelveInsight’s ‘Hunter Syndrome Market Insights, Epidemiology and Market Forecast 2030’ report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. About the Disease: Hunter Syndrome In patients with mucopolysaccharidosis II, glycosaminoglycans accumulate within tissues and organs, contributing to the signs and symptoms of the disease. Mucopolysaccharidosis II affects multiple organs and physiologic systems and has a variable age of onset and variable rate of progression. Common presenting features include excess urinary glycosaminoglycan excretion, facial dysmorphism, organomegaly, joint stiffness and contractures, pulmonary dysfunction, myocardial enlargement and valvular dysfunction, and neurologic involvement. In patients with neurologic involvement, intelligence is impaired, and death usually occurs in the second decade of life, whereas those patients with minimal or no neurologic involvement may survive into adulthood with normal intellectual development.

2. Click here to read more about Hunter Syndrome. Types of MPS II Severe MPS II Mild MPS II While both types affect many different organs and tissues as described above, people with severe MPS II also experience a decline in intellectual function and a more rapid disease progression. Individuals with severe form begin to lose basic functional skills (developmentally regress) between the ages of 6 and 8. The life expectancy of these individuals is 10–20 years. Individuals with mild MPS II also have a shortened lifespan, but they typically live into adulthood, and their intelligence is not affected. Heart disease and airway obstruction are major causes of death in people with both types of MPS II. Request for a free sample copy of the report: https://www.delveinsight.com/sample- request/hunter-syndrome-market Hunter Syndrome Diagnosis The diagnosis of Hunter syndrome is established in a male by identifying the deficient iduronate 2-sulfatase (I2S) enzyme activity in white cells, fibroblasts, or plasma in the presence of normal activity of at least one other sulfatase. Detection of a hemizygous pathogenic variant in IDS confirms the diagnosis in a male with an unusual phenotype or a phenotype that does not match the results of GAG testing. The diagnosis of this indication is usually established in a female with suggestive clinical features by identification of a heterozygous IDS pathogenic variant on molecular genetic testing. Hunter Syndrome Treatment Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood or bone marrow is a potential way of providing sufficient enzyme activity to slow or stop the progression of the disease, however, the use of HSCT is controversial because of the associated high risk of morbidity and mortality. The use of HSCT has been controversial because of limited information regarding the long-term outcomes and the associated high risk of morbidity and mortality. Click here and read more about Hunter Syndrome Diagnosis and Treatment Hunter Syndrome Epidemiology

3. The Hunter Syndrome epidemiology covered in the report provides historical, forecasted epidemiology segmented by Total Diagnosed Prevalent Population and Severity-based Diagnosed Prevalent Population of Hunter Syndrome in the 7MM market. Key Findings • The total Hunter Syndrome diagnosed prevalent population in the 7 major markets was found to be 1,145 in 2017. In case of Hunter Syndrome patients in the United States, the diagnosed prevalent cases were found to be 503 in 2017. Get more useful insights: https://www.delveinsight.com/report-store/hunter-syndrome- market Hunter Syndrome Marketed Therapies Assessment Elaprase by Takeda Hunter Syndrome Marketed Therapies Assessment JR-141 by JCR Pharmaceuticals TAK-609 by Takeda GC1111 by Green Cross Corporation/GC Pharma DNL310 by Denali Therapeutics RGX-121 by Regenxbio SB-913 by Sangamo Therapeutics Hunter Syndrome Market Outlook According to the National Organization for Rare Disorders (NORD), Hunter Syndrome (MPS II) is a rare lysosomal inborn error of metabolism that affects every organ of the body. Though the onset age, disease severity and the rate of progression of the disease vary significantly, initial symptoms and findings associated with the indication usually become apparent in children from 2–4 years of age. Hunter Syndrome typically affects only males as it is an X-linked recessive genetic condition. The disorder occurs in approximately 1 in 100,000 to 1 in 170,000 male births. A few affected females have been observed as well, due to the selective inactivation of the X chromosome inherited by the father. Key Findings

4. • The United States accounts for the largest Hunter Syndrome market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. • Among the EU5 countries, Germany had the highest market size with USD 20.09 Million in 2017, while Spain had the lowest market size of Hunter Syndrome with USD 12.49 Million in 2017, during the forecast period 2017–2030. Visit our repository of reports @https://www.delveinsight.com/report- store.php